Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-4347

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 70518-4347). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This text is a description of Fluticasone Propionate and Salmeterol Inhalation Powder. It is a prescription medication with a strength of 250mcg/50mcg. The medication comes in a package of 60 blisters and should be stored in a dry place away from direct heat or sunlight. The medication is for oral inhalation only and should be kept out of reach of children. The product is to be stored at a temperature of 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). The medication is manufactured by Prasco Laboratories and repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

This text appears to contain data related to a study or clinical trial evaluating the change in Forced Expiratory Volume (FEV) in patients taking different medications. The study involves comparing the effects of Fluticasone propionate/salmeterol combination, Fluticasone propionate alone, Salmeterol alone, and a placebo on FEV over time. The data includes percentages of change in FEV at various time points and dosages of the medications administered.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

This text provides information about a study comparing different treatments' effects on lung function, measured by Forced Expiratory Volume in 4 seconds (FEV4). The study includes groups receiving a combination of Fluticasone propionate and salmeterol, salmeterol alone, Fluticasone propionate alone, and a placebo. The data suggests a 9% change in FEV4 across the different treatment groups.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

This text appears to be a table showing the percentage change in FEV (Forced Expiratory Volume) relative to the Day 1 baseline across different treatment groups. The treatments listed include Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The data seems to be presented over a 12-week period.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

This text appears to be a partial excerpt related to the comparison of Fluticasone propionate/salmeterol DISKUS 250/50 mcg dose with Salmeterol 50 mcg dose and placebo in terms of FEV1 values over a week. The data shows values for different time points (weeks) for each treatment group. The comparison indicates the efficacy of the different doses in relation to FEV1 levels.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

This appears to be a description of a medication product called "Putiasone" with Salmeterol Diskus inhalation powder. It seems to be mentioning a dosage of 100 mcg/50 mcg per actuation. The product likely includes a mouthpiece and a lever for dispensing the medication.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

FDA Label Image

Figure D (Fp Sal Spl Graphic 11)

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

FDA Label Image

Figure G (Fp Sal Spl Graphic 14)

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.